Stensen duct dilation: Case series of minimally invasive treatment

Marc-Kevin Le Roux (1) , Nicolas Graillon (1, 2) , Mehdi Hadj-Saïd (1) , Ugo Scemama (3) , Jean-Christophe Lutz (4) , Cyrille Chossegros (1, 5)

1 Service de chirurgie maxillo-faciale et de stomatologie [Hôpital de la Conception - APHM]
2 CEReSS - Centre d'études et de recherche sur les services de santé et la qualité de vie
3 Hôpital Nord [CHU - APHM]
4 Hôpital de Hautepierre [Strasbourg]
5 LPL - Laboratoire Parole et Langage

Stensen's duct dilation is a rare condition characterized by a global or partial idiopathic dilation of the Stensen duct. Affected individuals usually show either aesthetically compromised features, such as a tubular-shaped swelling in the cheek, or with mildly painful inflammatory episodes. Three women between ages 61 and 67years were diagnosed with Stensen duct dilation after sialo-magnetic resonance imaging (MRI). They were treated with botulinum toxin A (BTX-A). Our preliminary results suggest that BTX-A was efficient as a suspensive treatment. BTX-A should remain a first-line treatment of the early silent symptoms of Stensenduct dilation, such as swelling and aesthetic issues. The use of BTX-A avoids more serious procedures and further complications. Copyright © 2019 Elsevier Inc. All rights reserved.

Domaines: Chirurgie

Marc-Kevin Le Roux, Nicolas Graillon, Mehdi Hadj-Saïd, Ugo Scemama, Jean-Christophe Lutz, et al.. Stensen duct dilation: Case series of minimally invasive treatment. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2019, ⟨10.1016/j.oooo.2019.01.078⟩. ⟨hal-02102540⟩